Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Adaptive Biotechnologies Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
| Adaptive Biotechnologies Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
| Adaptive Biotechnologies Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
| Adaptive Biotechnologies Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
| Adaptive Biotechnologies Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
| Adaptive Biotechnologies Corporation, Medical Equipment, Deal Details | 11 | 13 |
| Venture Financing | 11 | 1 |
| Sequenta Raises Funds through Venture Financing | 11 | 1 |
| Sequenta Raises US$20 Million In Series C Financing | 12 | 1 |
| Sequenta Raises US$8.5 Million In Venture Financing | 13 | 1 |
| Sequenta Secures US$13 Million In Series B Financing | 14 | 1 |
| MLC Dx Secures US$6 Million In Venture Financing | 15 | 1 |
| Partnerships | 16 | 1 |
| Sequenta Enters Into Licensing Agreement With iRepertoire | 16 | 1 |
| Argos Therapeutics Enters into Research Agreement with Adaptive Biotechnologies | 17 | 1 |
| Propanc Health Enters into Research Agreement with Adaptive Biotech | 18 | 1 |
| Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit | 19 | 1 |
| Adaptive Biotech Enters Into Biomarker Discovery Agreement With Johnson &Johnson Innovation | 20 | 1 |
| Adaptive Biotech Enters Into Co-Development Agreement With Bristol-Myers Squibb | 21 | 1 |
| Acquisition | 22 | 1 |
| Adaptive Biotech Acquires Sequenta | 22 | 2 |
| Adaptive Biotechnologies Corporation - Key Competitors | 24 | 1 |
| Key Employees | 25 | 1 |
| Locations And Subsidiaries | 26 | 1 |
| Head Office | 26 | 1 |
| Other Locations &Subsidiaries | 26 | 1 |
| Recent Developments | 27 | 1 |
| Corporate Communications | 27 | 1 |
| Apr 11, 2016: Adaptive Biotechnologies Welcomes Charles Sang as Senior Vice President of Diagnostics | 27 | 1 |
| Mar 15, 2016: Innovation Leader, Diego Miralles, M.D., Joins Adaptive Biotechnologies as President of Adaptive Therapeutics | 28 | 1 |
| Aug 10, 2015: Adaptive Biotechnologies Welcomes Chad Cohen As Its New Chief Financial Officer | 29 | 1 |
| Mar 03, 2015: Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors | 30 | 1 |
| Product News | 31 | 1 |
| Dec 07, 2015: Adaptive Biotechnologies and Collaborators Present New Data Showing Minimal Residual Disease Predicts Relapse and Survival in Chronic Lymphocytic Leukemia Patients | 31 | 1 |
| May 11, 2015: Adaptive Biotechnologies immunoSEQ Assay Provides Groundbreaking Insight into T-Cell Fate, Significantly Advancing Understanding of Adaptive Immunity | 32 | 1 |
| May 08, 2015: Adaptive Biotechnologies and Collaborators to Present 5 Studies Demonstrating Utility of Immunosequencing to Determine T-cell Function in Chronic and Infectious Diseases at the 2015 American Association of Immunologists Annual Meeting | 33 | 2 |
| Apr 28, 2015: Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin s Lymphoma in Blood | 35 | 1 |
| Apr 22, 2015: Adaptive Biotechnologies clonoSEQ Minimal Residual Disease Test Detects Relapse with Higher Specificity than PET/CT in Diffuse Large B-Cell Lymphoma Patients | 36 | 1 |
| Apr 15, 2015: Adaptive Biotechnologies and Collaborators to Present 4 Studies Demonstrating Clinical Relevance of Immunosequencing in the Treatment of Solid Tumors at the 2015 American Association for Cancer Research Annual Meeting | 37 | 2 |
| Apr 01, 2015: Adaptive Biotechnologies clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA | 39 | 1 |
| Appendix | 40 | 1 |
| Methodology | 40 | 1 |
| About GlobalData | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 40 | 1 |
